Full-Time

Clinical Laboratory Scientist I

Generalist or CGMBS

Posted on 4/5/2025

Delfi Diagnostics

Delfi Diagnostics

51-200 employees

Advanced cancer detection using DNA analysis

Compensation Overview

$57.69 - $61.53/hr

Entry, Junior

Palo Alto, CA, USA

DELFI has 1-2 designated in-office working days each week for employees who live within 50 miles of Palo Alto CA or Baltimore MD offices

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Requirements
  • Must possess an active and valid Clinical Laboratory Scientist (CLS) Generalist license or the Clinical Laboratory Scientist CGMBS license issued by the state of California pursuant to Division 2, Chapter 3 of the California Business and Professions Code or to practice medicine, osteopathy, or podiatry pursuant to Division 2, Chapter 5 of the California Business and Professions Code appropriate to the specialty being performed.
  • Must fulfill requirements stated in 42 CFR 493.1489 or 493.1491
  • Must fulfill requirements stated in the College of American Pathologists Molecular Pathology Checklist
  • BS in Biomedical Laboratory Sciences, Clinical Science, or equivalent
  • Ability to communicate complex technical results to a cross-functional audience.
  • Desire to learn about cancer genetics and contribute to a diverse, collaborative, and mutually respectful working environment.
Responsibilities
  • Perform laboratory tests, procedures, analyses, and release patient results per approved procedure
  • Identify and troubleshoot high complexity problems that may adversely affect test performance
  • Perform and document reagent manufacturing and qualification per approved procedures
  • Verify instrument performance through inspection, calibration, and maintenance per approved procedures
  • Help conduct the training of new and existing laboratory personnel on current and new procedures.
Desired Qualifications
  • 1+ years of Clinical Laboratory experience or equivalent high complexity and volume laboratory experience
  • Laboratory experience within the last year
  • Experience with next-generation sequencing, molecular biology techniques, and automated liquid handlers
  • Working knowledge of local, state, and federal laboratory regulations

Delfi Diagnostics focuses on early cancer detection using advanced machine learning and fragmentomics, which involves analyzing fragments of cell-free DNA. Their technology differs from traditional methods by scanning millions of data points to find previously unrecognized cancer-associated fragments, allowing for a more thorough and potentially earlier diagnosis. The company is led by a team of experts in cancer biology, bioinformatics, and machine learning, with Dr. Victor Velculescu as the CEO, who is well-known in the field of genomics. Delfi Diagnostics aims to provide healthcare providers and patients with effective cancer detection services, positioning itself as a leader in healthcare technology.

Company Size

51-200

Company Stage

Series B

Total Funding

$330.5M

Headquarters

Baltimore, Maryland

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Fragmentomics is gaining traction, enhancing Delfi's early cancer detection capabilities.
  • AI integration in genomics accelerates, benefiting Delfi's technology advancements.
  • Demand for non-invasive cancer screening aligns with Delfi's blood-based test focus.

What critics are saying

  • City of Hope's new test may compete with Delfi's early detection capabilities.
  • New executive appointments may disrupt operations or delay projects.
  • Collaboration with Incendia Therapeutics introduces risks if clinical trial outcomes are unfavorable.

What makes Delfi Diagnostics unique

  • Delfi uses fragmentomics for early cancer detection, unlike traditional mutation-focused methods.
  • Their technology scans millions of data points for unrecognized cancer-associated fragments.
  • Delfi's team includes experts in genomics, bioinformatics, and regulated software development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Parental Leave

Flexible Time Off

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

3%
Bizjournals
Oct 30th, 2024
8 things to know: New Under Armour HQ almost complete

Canton-based Delfi Diagnostics has named Robert Guigley as its new chief commercial officer.

PR Newswire
Oct 28th, 2024
DELFI Diagnostics Working with Incendia Therapeutics to Employ Advanced Treatment Monitoring Test in a Phase 1 Clinical Trial

DELFI Diagnostics working with Incendia Therapeutics to employ advanced treatment monitoring test in a Phase 1 clinical trial.

PR Newswire
Aug 26th, 2024
DELFI Diagnostics Appoints Thomas Russo as Chief Financial Officer

DELFI Diagnostics appoints Thomas Russo as Chief Financial Officer.

Finsmes
Jun 5th, 2024
DELFI Diagnostics Receives Equity Investment From Merck Global Health Innovation Fund

DELFI Diagnostics receives equity investment from Merck Global Health Innovation Fund.

CityBiz
Jun 4th, 2024
DELFI Diagnostics Gains Merck Investment

DELFI Diagnostics announced an equity investment from the Merck Global Health Innovation Fund to accelerate the development and commercialization of its cancer detection solutions. DELFI's technology uses AI and whole-genome sequencing to analyze cfDNA patterns for early cancer detection. The investment aims to enhance detection and treatment monitoring for cancer patients. DELFI's FirstLook Lung test has shown 80% sensitivity and 99.8% NPV in detecting lung cancer.

INACTIVE